CHAPTER 46
HB 89-FN - FINAL VERSION
7Apr2021... 0437h
2021 SESSION
21-0084
11/04
HOUSE BILL 89-FN
AN ACT adding qualifying medical conditions to the therapeutic use of cannabis law.
SPONSORS: Rep. Vail, Hills. 30; Rep. Chase, Straf. 18; Rep. Laflamme, Coos 3; Rep. Abramson, Rock. 37
COMMITTEE: Health, Human Services and Elderly Affairs
─────────────────────────────────────────────────────────────────
AMENDED ANALYSIS
This bill adds moderate to severe insomnia and autism spectrum disorder to the definition of "qualifying medical condition" for the purposes of the use of cannabis for therapeutic purposes law.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
7Apr2021... 0437h 21-0084
11/04
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Twenty One
AN ACT adding qualifying medical conditions to the therapeutic use of cannabis law.
Be it Enacted by the Senate and House of Representatives in General Court convened:
46:1 Use of Cannabis for Therapeutic Purposes; Definitions. Amend RSA 126-X:1, IX(a)(2) to read as follows:
(2) A severely debilitating or terminal medical condition or its treatment that has produced at least one of the following: elevated intraocular pressure, cachexia, chemotherapy-induced anorexia, wasting syndrome, agitation of Alzheimer's disease, severe pain that has not responded to previously prescribed medication or surgical measures or for which other treatment options produced serious side effects, constant or severe nausea, moderate to severe vomiting, seizures, [or] severe, persistent muscle spasms, or moderate to severe insomnia; or
46:2 New Subparagraphs; Use of Cannabis for Therapeutic Purposes; Definitions. Amend RSA 126-X:1, IX(b) by inserting after subparagraph (3) the following new subparagraphs:
(4) Autism spectrum disorder in adults 21 years of age or older.
(5) Autism spectrum disorder in people under 21 years of age with the requirement of a consultation with a certified provider of child and/or adolescent psychiatry, developmental pediatrics, or pediatric neurology, who confirms that the autism spectrum disorder has not responded to previously prescribed medication or for which other treatment options produced serious side effects and who supports certification for the use of therapeutic cannabis.
46:3 Effective Date. This act shall take effect 30 days after its passage.
Approved: May 25, 2021
Effective Date: June 24, 2021